Novel Strategies to Reverse Drug Resistance

• 7112 · PDF Understanding and overcoming resistance of triple-negative breast cancer brain metastases to RET monotherapy Phi-Long Tran, Elissa Bloom, Angelina Regua, Shivani Bindal, Mariana Najja, Sham Syed, Hui-Wen Lo
• 7113 · PDF Targeting breast cancer brain metastasis through novel combination of FDA-approved orally active BBB-permeable RET and tGLI1 inhibitors Joshua Cha, Angelina Regua, Mariana Najjar, Shivani Bindal, Elissa Bloom, Hui-Wen Lo
• 7114 · PDF Therapeutic potential of BTK targeted degrader in B-cell malignancies harboring ibrutinib-resistant mutation Shuai Zhao, Xiujuan Wu, Ting Ni, Jian Xiang, Zhixiang Zhang
• 7117 · PDF Pharmacological disruption of YAP1/TEAD and NF-kappa B crosstalk suppresses prostate cancer Sebnem Unlu, Abdulrahman M. Dwead, Marwah M. Al-Mathkour, Bekir Cinar
• 7118 · PDF TNKS inhibition rewires AMOT-YAP signaling to overcome YAP-driven therapy resistance in solid tumors Jae Sung Kim, Young-Ju Kwon, Dong Young Kim, Yuna Kim
• 7119 · PDF Large-scale drug screening identifies clinically actionable combinations to overcome BTK/PI3K inhibitor resistance in marginal zone lymphoma Alberto J. Arribas, Elena Mariotto, Eleonora Cannas, Giampietro Viola, Francesco Bertoni
• 7120 · PDF Rinzimetostat, an allosteric EED inhibitor with best-in-class properties for the treatment of prostate cancer, is effective in PRC2 methyltransferase-resistant settings in preclinical studies Xi Chen, Livia Ulicna, Eunice Lopez-Fuentes, Anjana Ramnath, Ashley Pereira, Archana Kumar, Robert Warne, Kyle A. Edgar, Aleksandr Pankov, Jason E. Long, Ajit Narang, Lori S. Friedman, Anneleen Daemen, Melissa R. Junttila
• 7121 · PDF CRISPR druggable-genome screen identifies BRD4 as a synergistic vulnerability with the natural product cerberin in pancreatic cancer organoids Md Shahadat Hossan, Lauryn E. Flannagan, Michela Cadarso, Molly A. Nellen, Ethan S. Lin, Austin Stram, Dustin Rubinstein, Derek Pavelec, Mark E. Berres, Sean Ronnekleiv-Kelly, Jeremy D. Kratz
• 7122 · PDF Nanoparticle-mediated restoration of pomalidomide sensitivity in multiple myeloma Joseph Uche Ogbede, Kaiqi Long, Michael S. Rogers, Jinjun Shi, Robert J. D'Amato, Bruce R. Zetter
• 7123 · PDF QW-5-70 targets the colchicine site to overcome multidrug resistance and shows potent antitumor activities Yang Xie, Ruida Hou, Najah Albadari, Hao Chen, Darcie J. Miller, Judith Quadrozzi Gruntz, Michael L. Oldham, Mir Shahriar Kamal, Jianxiong Jiang, Zhongzhi Wu, Duane D. Miller, Wei Li
• 7124 · PDF Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy Shelby K. Yee, Hendrien Kuipers, Danielle M. Carlson, Jack W. Sample, Enis Ozmert, Hidemi Nishi, Erik Jessen, Dong-Gi Mun, Aushinie M. Abeynayake, Jennifer L. Tomlinson, Amro M. Abdelrahman, Nathan W. Werneburg, Binbin Li, Mitesh J. Borad, Mark J. Truty, Sumera I. Ilyas, Gregory J. Gores, Rory L. Smoot
• 7125 · PDF Mechanistic basis of resistance to HDAC6 inhibitors reveals proteasome inhibition as a rational combination strategy in breast cancer Jose Silva, Tizita Zewde Zeleke, Qingfei Pan, Jiyang Yu
• 7126 · PDF Targeting Aurora A kinase together with alternative survival signaling overcomes resistance to endocrine and CDK4/6 therapies in ER+ breast cancer Chia-Chia Liu, Alekya Raghavan, Lanfang Qin, Sarmistha Nanda, Fu-Tien Liao, Georg F. Bischof, Mothaffar F. Rimawi, C. Kent Osborne, Jamunarani Veeraraghavan, Rachel Schiff
• 7127 · PDF RalBP1 inhibition: A novel therapy for prostate cancer Sharad S. Singhal, Madhu Krishna, Prakash Kulkarni, David Horne, Ravi Salgia
• 7128 · PDF The rise of YAP: A new hope in glioblastoma treatment Shuhan Cao, Ethan C. L. Wong, Gilberto K. K. Leung, Karrie M. Y. Kiang
• 7129 7129 Targeting PARPi drug tolerant persistence and progression on treatment with clinical stage ATM inhibitors in advanced prostate cancer Akshaya Karthikeyan, Bryan Correa Gonzalez, Jose G. Torres-Gonzalez, Love A. Moore, Anamitra Bhaumik, Ethan Sandoval, Alan P. Lombard
• 7130 · PDF GRN-300 restores PARP inhibitor sensitivity through inhibition of the HDAC-MEF2A-RAD51 pathway in BRCA2-revertant ovarian cancer Carlos Flores Suarez, Janice M. Santiago-O'Farrill, Weiqun Mao, Hailing Yang, Zhen Lu, Robert C. Bast
• 7131 · PDF Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer Sa deok Hong, Min Sil Kang, Nar Katuwal, Mithun Ghosh, Seong Min Park, Kim Ju Hyeon, Seul-Gi Kim, Yong Wha Moon
• 7132 · PDF Rinzimetostat blockade of PRC2 activity, a key mechanism of treatment resistance, improves response of androgen receptor pathway inhibition across a spectrum of prostate cancer models Aleksandr Pankov, Amber W. Wang, Natalie Yuen, Livia Ulicna, Jason E. Long, Xi Chen, Gina Andretta, Lori S. Friedman, Melissa R. Junttila, Anneleen Daemen
• 7133 · PDF Combined anti-CSF-1R and anti-TIM-3 overcome macrophage-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancer Adam Nelson, Anita K. Mehta, Madeline G. Townsend, Daniel E. Michaud, Madisson Oliwa, Kelly F. Zheng, Carlos W. S. Wanderley, Alex P. Gottlieb, Kenichi Shimada, Patrice A. Lee, Nicholas A. Saccomano, Filipa Lynce, Nabihah Tayob, Geoffrey I. Shapiro, Jennifer L. Guerriero
• 7134 · PDF Developing drug combinations with AMG 193, a novel MTA-cooperative PRMT5 inhibitor, using patient-derived xenograft models of MTAP -deleted non-small cell lung cancer and mesothelioma Florence T. H. Wu, Nhu-An Pham, Yu-Hui Wang, Ming Li, Nikolina Radulovich, Katrina Hueniken, Quan Li, Siyuan (Claret) Liu, Brian Belmontes, Paul Hughes, Ming-Sound Tsao, Adrian Sacher
• 7135 · PDF A first-in-class orally bioavailable small molecule to overcome treatment resistance in hormone receptor-positive breast cancer Hee-Sung Park, Chakrapani Subramanyam, Kyu-kwang Cho, Se Hee Hyun, Yeonjee Kahm
• 7137 · PDF Targeting RRM2 to enhance PARP inhibitor sensitivity in TNBC Tamanna Islam, Howard L. Elford, Jesika S. Faridi
• 7138 · PDF Acquired saruparib (AZD5305) resistance in BRCA1-deficient triple negative breast cancer is vulnerable to DNA damage response-targeted therapeutics Matthew R. Jordan, Pamela S. VanderVere-Carozza, Jessica Lynn Kersey, Katherine Pawelczak, John J. Turchi
• 7139 · PDF Uncovering PGRMC1-PARP interaction: A novel combination therapeutic strategy in triple-negative breast cancer Mahalakshmi Vijayaraghavan, Ramadevi Subramani, Michel Rojo Amador, Kyle Nguyen, Kariina Garcia, Poornima Devi Narayanan, Alfredo Roman, Abigail Ramirez, Jazmin Lopez, Rajkumar Lakshmanaswamy
• 7140 · PDF Synthetic lethality of Hsp90beta-selective inhibition with PARPi in homologous recombination repair proficient ovarian cancer Sanket Mishra

在会议检索中浏览本分会场